Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 4, fMRI Study of Treatment Recommendations Comparing Patients Taking IFN-β-1a 44 Mcg Tiw SC (Rebif) to Controls of Patients Recently Diagnosed With Relapsing Remitting Multiple Sclerosis Currently Naive to Disease-Modifying Therapy.

Next Previous
Search
Trial Profile

A Phase 4, fMRI Study of Treatment Recommendations Comparing Patients Taking IFN-β-1a 44 Mcg Tiw SC (Rebif) to Controls of Patients Recently Diagnosed With Relapsing Remitting Multiple Sclerosis Currently Naive to Disease-Modifying Therapy.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Glatiramer acetate; Interferon beta-1a
  • Indications Multiple sclerosis
  • Focus Biomarker; Therapeutic Use

Most Recent Events

  • 04 Jun 2014 Biomarkers information updated
  • 01 Aug 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
  • 29 Oct 2010 Official Title amended as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top